Back to top
more

Dare Bioscience (DARE)

(Real Time Quote from BATS)

$0.41 USD

0.41
48,142

-0.02 (-4.38%)

Updated Jun 6, 2024 11:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for DARE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Dare Bioscience, Inc. [DARE]

Reports for Purchase

Showing records 161 - 180 ( 213 total )

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 161

12/06/2019

Company Report

Pages: 23

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 162

11/15/2019

Company Report

Pages: 8

3Q19 Marching Forward in Women''s Health, Led by Ovaprene and BV

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 163

11/15/2019

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 164

11/12/2019

Company Report

Pages: 10

Ovaprene Hits its Primary Endpoint

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 165

11/12/2019

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 166

11/12/2019

Daily Note

Pages: 5

Win for Ovaprene PCT Opens the Door to a Single Pivotal Trial

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 167

11/11/2019

Company Report

Pages: 9

Dare Goes for Blue Tooth Drug Delivery, Set to Acquire Microchips Biotech and Picks up $5.7M

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 168

10/11/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 169

10/10/2019

Company Report

Pages: 9

Takeaways from our Doc Call with Dr. Jane Schwebke

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 170

10/04/2019

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 171

10/03/2019

Company Report

Pages: 8

Learn the ABC''s of BV on our Expert Call on Oct. 9th at 12PM ET

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 172

09/17/2019

Industry Report

Pages: 9

Healthcare Additional Doc Calls to Pricing

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 173

09/10/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 174

09/10/2019

Company Report

Pages: 10

Meaningful Milestones Ahead including FSAD

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 175

09/09/2019

Company Report

Pages: 5

There Is a Ray at the End of the FSAD Tunne

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 176

09/03/2019

Industry Report

Pages: 7

Healthcare- Join Our Doc Call Series on Drug Pricing

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 177

08/15/2019

Industry Report

Pages: 4

Healthcare - Earnings Recap: The More Analysis, The Merrier, Especially When Data-Driven

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 178

08/15/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 179

08/15/2019

Company Report

Pages: 9

2Q19: Anticipation Is Building for Key 4Q19 Updates in BV1 and Ovaprene

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 180

08/15/2019

Company Report

Pages: 10

Reports the Quarter -Meaningful Milestones Ahead

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party